Information Related to Clinical Trials
TaiRx’s novel anti-cancer drug CVM-1118 and add-on therapy for sepsis drug Rexis® are currently in Phase II and Phase III clinical trials, respectively.
Clinical trial of Rexis® as an add-on therapy for patients with sepsis and septic shock
- Center for Drug Evaluation, Taiwan:(Click here)
If you would like to know more information regarding the clinical trials, please contact the nearest clinical trial center.
News
Mr. Andrew Lin’s appointment as Chairman of TaiRx, Inc. is effective as of December 9, 2020.
2020/12/9 Andrew Lin received his master’s degree of Business [...]
TaiRx’s anti-cancer drug CVM-1118 won the renewal of Excelsior Award in 2020.
2020/12/1 Having been awarded the 12th National Innovation Award [...]
TaiRx successfully raised 504 million NTD in capital.
2020/11/27 To enrich working capital, TaiRx has successfully raised [...]